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Sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) plays a central role in the
pathogenesis of diabetes. This protein has been recognized as a potential target
for diabetic therapy. In this study, we identified astragaloside IV (AS-IV) as a potent
modulator of SERCA inhibiting renal injury in diabetic status. Increasing doses of AS-
IV (2, 6, and 18 mg kg−1 day−1) were administered intragastrically to db/db mice for
8 weeks. Biochemical and histopathological approaches were conducted to evaluate
the therapeutic effects of AS-IV. Cultured mouse podocytes were used to further explore
the underlying mechanism in vitro. AS-IV dose-dependently increased SERCA activity
and SERCA2 expression, and suppressed ER stress-mediated and mitochondria-
mediated apoptosis in db/db mouse kidney. AS-IV also normalized glucose tolerance
and insulin sensitivity, improved renal function, and ameliorated glomerulosclerosis and
renal inflammation in db/db mice. In palmitate stimulated podocytes, AS-IV markedly
improved inhibitions of SERCA activity and SERCA2 expression, restored intracellular
Ca2+ homeostasis, and attenuated podocyte apoptosis in a dose-dependent manner
with a concomitant abrogation of ER stress as evidenced by the downregulation of
GRP78, cleaved ATF6, phospho-IRE1α and phospho-PERK, and the inactivation of both
ER stress-mediated and mitochondria-mediated apoptotic pathways. Furthermore,
SERCA2b knockdown eliminated the effect of AS-IV on ER stress and ER stress-
mediated apoptotic pathway, whereas its overexpression exhibited an anti-apoptotic
effect. Our data obtained from in vivo and in vitro studies demonstrate that AS-IV
attenuates renal injury in diabetes subsequent to inhibiting ER stress-induced podocyte
apoptosis through restoring SERCA activity and SERCA2 expression.
Keywords: astragaloside IV, diabetic nephropathy, sarco/endoplasmic reticulum Ca2+-ATPase 2, endoplasmic
reticulum stress, podocyte apoptosis
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INTRODUCTION
Diabetic nephropathy remains the most common microvascular
complication of diabetes and the leading cause of end-stage-renal
disease (ESRD) worldwide. Recently, accumulating evidence
have indicated that podocyte apoptosis plays an important role
in the pathogenesis of DN (Reidy et al., 2014). However, the
underlying mechanism is not completely understood.
Endoplasmic reticulum is a cellular organelle that is
responsible for protein processing. Some pathophysiological
stress leads to the accumulation of aberrant unfolded proteins
in the ER lumen, which in turn initiates a well-conserved
signaling cascade called the UPR to mitigate ER stress through
the mediation of three ER-resident transducers: activating
transcription factor 6 (ATF6), PERK, and IRE1 (Inagi, 2010; Inagi
et al., 2014). However, under prolonged or excessive ER stress,
the apoptotic signaling will be induced, leading to cell injury and
death through the mediation of downstream molecules, such as
CHOP, c-Jun N-terminal kinases (JNK), and caspase 12 (Inagi,
2010; Inagi et al., 2014). Recently, ER stress has emerged as one
of the central mechanisms that lead to diabetic complications and
inhibition of ER stress improves diabetic symptoms (Ozcan et al.,
2006; Qi et al., 2011). Excessive ER stress results in podocyte
apoptosis while suppression of ER stress attenuates podocyte
apoptosis in vivo and in vitro (Chen et al., 2008; Cao et al., 2016).
In addition to being a major intracellular storage site for
calcium (Ca2+), ER maintains its normal function depending
heavily on intraluminal calcium concentrations (Ashby and
Tepikin, 2001; Vangheluwe et al., 2005). Perturbation of ER Ca2+
homeostasis leads to ER stress and the activation of UPR (Ron
and Walter, 2007; Ozcan and Tabas, 2012). The SERCA, which
pumps cytosolic Ca2+ into the ER, is an imperative maintainer
of ER Ca2+ homeostasis (Ashby and Tepikin, 2001; Vangheluwe
et al., 2005). The mammalian SERCA family is comprised of three
tissue-specific members, SERCA1-3, with SERCA2 being the
most widespread isoform (Ashby and Tepikin, 2001; Vangheluwe
et al., 2005). Several investigations have revealed a loss of SERCA2
isoform b (SERCA2b) expression and activity in islets (Cardozo
et al., 2005; Kono et al., 2012), heart (Wold et al., 2005; Takada
et al., 2012), and liver (Park et al., 2010; Fu et al., 2011) in selected
models of diabetes, suggesting that SERCA2 dysfunction is a
potential pathology for development of diabetic complications.
Disruption of ER Ca2+ homeostasis caused by impaired activity
or expression of SERCA2 triggers ER stress (Cardozo et al., 2005;
Fu et al., 2011), while increasing SERCA2 function by SERCA2
overexpression or SERCA2 activators alleviates ER stress and
improves diabetic conditions (Park et al., 2010; Kang et al., 2015).
Abbreviations: AIF, apoptosis-inducing factor; ANT, adenine nucleotide
translocase; APAF1, apoptosis protease-activating factor 1; AS-IV, astragaloside
IV; ASK1, apoptosis signal-regulating kinase 1; ATF, activating transcription
factor; BUN, blood urea nitrogen; CHOP, C/EBP homology protein; DN, diabetic
nephropathy; eIF2α, eukaryotic translation initiation factor 2α; ER, endoplasmic
reticulum; GRP78, glucose-regulated protein 78; HOMA-IR, homeostatic model
assessment of insulin resistance; IOD, integrated optical density; IRE1, inositol-
requiring enzyme 1; PAS, periodic acid-Schiff; PERK, protein kinase R-like ER
kinase; PPARγ, peroxisome proliferator-activated receptor γ; RGZ, rosiglitazone;
SERCA, sarco/endoplasmic reticulum Ca2+-ATPase; siRNA, small interference
RNA; UPR, unfolded protein response; XBP1, X-box binding protein 1.
Saponin AS-IV is one of the active components of Astragalus
membranaceus (Fisch) Bge, which has been shown to possess
comprehensive pharmacological activities in treating renal
diseases (Rios and Waterman, 1997; Peng et al., 2008). A body
of studies have addressed the renoprotective role of AS-IV,
including suppressing renal inflammation (Gui et al., 2013),
inhibiting renal tubulointerstitial fibrosis (Wang et al., 2014a,b),
and protecting podocytes (Gui et al., 2012; Chen et al., 2014a).
Recent investigations show that AS-IV attenuates proteinuria
and podocyte apoptosis in streptozotocin-induced DN via the
inhibition of ER stress (Chen Y. et al., 2014; Wang et al.,
2015), but the underlying mechanism needs to be further
elucidated. The reports that SERCA2b is a major regulator
of ER stress (Park et al., 2010) and AS-IV can modulate
SERCA2a expression in myocardial injury (Xu et al., 2007,
2008) prompt us to test whether AS-IV alleviates ER stress
through regulating SERCA. Therefore, the current study is
undertaken to define whether SERCA2 is implicated in the
renoprotective effect of AS-IV in db/db mice, a mouse model of
type 2 diabetes, and palmitate-stimulated mouse podocyte cell
line.
MATERIALS AND METHODS
Drugs
Astragaloside IV was purchased from Shanghai Bogoo
Biotechnology Company, Limited (purity at 98%, Shanghai,
China). RGZ was purchased from Sigma-Aldrich (St. Louis, MO,
USA).
Animals and Drug Administration
db/db mouse exhibits clinical and histological features of DN
resembling those found in human DN, such as hyperglycemia,
hyperinsulinemia, hyperlipidemia, obesity, albuminuria,
glomerular enlargement, and mesangial matrix expansion
(Sharma et al., 2003; Tesch and Lim, 2011). Six-week-old male
diabetic db/db (BKS.cg-m +/+ Leprdb/J) and age-matched non-
diabetic db/m littermates were purchased from Model Animal
Research Center of Nanjing University (Nanjing, China). All the
work was carried out in accordance with the approved guidelines
for the use of experimental animals in Putuo Hospital, Shanghai
University of Traditional Chinese Medicine. The BKS.cg-m +/+
Leprdb/J mouse becomes obese and diabetic by 8 weeks of age.
They were housed in Experimental Animal Facilities at Shanghai
Putuo District Central Hospital under specific-pathogen-free
(SPF) conditions. Animals were fed with standard diet and free
to water. At 8 weeks of age, db/m and db/db mice were randomly
assigned to seven groups (n = 10/each group): (1) normal
db/m mice receiving vehicle (db/m-vehicle), (2) db/m mice
receiving AS-IV at 18 mg kg−1 day−1 (db/m-18 mg kg−1 day−1
AS-IV), (3) diabetic control db/db mice receiving vehicle (db/db-
vehicle), (4) db/db mice receiving AS-IV at 2 mg kg−1 day−1
(db/db-2 mg kg−1 day−1 AS-IV), (5) db/db mice receiving
AS-IV at 6 mg kg−1 day−1 (db/db-6 mg kg−1 day−1 AS-IV),
(6) db/db mice receiving AS-IV at 18 mg kg−1 day−1 (db/db-
18 mg kg−1 day−1 AS-IV), and (7) db/db mice receiving RGZ as
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the positive control at 2 mg kg−1 day−1 (db/m-2 mg kg−1 day−1
RGZ). AS-IV and RGZ were suspended in 0.5% carboxymethyl
cellulose as a vehicle for their administrations and were given to
mice by oral gavage once daily for 8 weeks. Dose conversion from
human to animal was using the body surface area normalization
method (Reagan-Shaw et al., 2008).
Measurement of Metabolic and
Physiological Parameters
Body weight, food and water intake, urine volume, fasting
blood glucose, and systolic blood pressure were measured at 4-
week intervals. Mice were housed in individual metabolic cages
for 24 h urine collection. Fasting blood glucose levels were
monitored with the Omron HEA-230 Glucometer using one drop
of tail blood. Systolic blood pressure was obtained by tail-cuff
plethysmography using the ALC-NIBP blood pressure measuring
system (Shanghai Alcott Biotech Co., Ltd., Shanghai, China). At
the end of the study, blood samples were drawn from orbit and
centrifuged for serum collection. Then the animals were killed
and both kidneys were removed immediately. A portion of the
renal cortex was fixed in 4% paraformaldehyde for histological
examination. The rest of the renal cortex was snap-frozen in
liquid nitrogen and then stored at −80◦C for protein and
total RNA extraction, and for ER isolation. Urinary albumin
(albuminuria) was measured using an ELISA Kit (Biovision,
Milpitas, CA, USA) and urinary albumin excretion was expressed
as urinary albumin to creatinine ratio (ACR). BUN was measured
using Urea Nitrogen Colorimetric Detection Kit (Arbor Assays,
Ann Arbor, MI, USA). Urinary and serum creatinine levels were
determined by Creatinine Colorimetric/Fluorometric Assay Kit
(Biovision, Milpitas, CA, USA). Serum HbA1c was measured
using Mouse Glycated Hemoglobin (HbA1C) ELISA Kit (Wuxi
Donglin Sci &Tech Development Co., Ltd., Wuxi, China). Serum
insulin was measured using Rat/Mouse Insulin 96 Well Plate
Assay Kit (Millipore, Billerica, MA, USA). All the biochemical
parameters were determined according to the manufacturer’s
instructions. Insulin resistance was determined by calculating
the HOMA-IR. HOMA-IR index was calculated according
to the formula: HOMA-IR (mmol/L × µU/mL) = [fasting
glucose (mmol/l)] × [fasting insulin (µU/ml)]/22.5 (He et al.,
2014).
Oral Glucose Tolerance Test (OGTT) and
Intraperitoneal Insulin Tolerance Test
(IPITT)
After 8 weeks of treatment, mice were fasted for 6 h (8:00 AM
to 2:00 PM), and the oral glucose tolerance test (OGTT) and
intraperitoneal insulin tolerance test (IPITT) experiments were
performed as previously described (Chen et al., 2014b; Wang C.
et al., 2014). Briefly, the animals were orally administered with
glucose (2 g kg−1 body weight) or intraperitoneally administrated
with insulin (0.75 U kg−1 body weight), and blood glucose levels
were monitored over a 2 h period using Omron Glucometer.
Quantification of AUC was achieved using Graphpad Prism
software 5 software (GraphPad Software Inc., San Diego, CA,
USA).
Renal Histology and
Immunohistochemistry
Renal cortex was processed, embedded in paraffin and cut
into 5 µm-thick sections. Renal sections were stained with
PAS. Semiquantitative scoring of glomerular sclerosis was
performed in a blinded manner using a five-grade method
described previously (Taneda et al., 2003). Twenty to thirty
glomeruli randomly selected from per mouse were scored
from six mice in each group. For immunohistochemistry,
the sections were incubated with primary antibody against
Wilms’ tumor-1 (WT-1), Podocin, monocyte chemotactic
protein-1 (MCP-1), GRP78 (Abcam, Cambridge, MA, USA),
TNF-α (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
overnight at 4◦C, and then incubated with Biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA, USA)
followed by VECTASTAIN ABC Reagent (Vector Laboratories,
Burlingame, CA, USA) incubation for signal amplification. Color
development was achieved using 3,3′-diaminobenzidine (DAB)
(Vector Laboratories, Burlingame, CA, USA). The IOD was
assessed by computer analysis with Image-Pro plus 6.0 (Media
Cybernetics, MD, USA).
TUNEL Staining
TUNEL staining was performed with the ApopTag Plus
Peroxidase In Situ Apoptosis Detection Kit (Millipore, Billerica,
MA, USA) according to the manufacturer’s instructions. TUNEL-
positive cells were semiquantified by randomly counting at least
30 glomeruli in each mouse.
Western Blotting
Renal cortex or cultured podocytes were lysed with the buffer
containing 50 mM Tris (pH7.5), 150 mM NaCl, 1% Triton
X-100, 0.5% sodium deoxycholate, 2 mM EDTA, 0.5 mM
dithiothreitol, 1 mM PMSF, protease inhibitor cocktail and
phosphatase inhibitor (both from Sigma-Aldrich, St. Louis,
MO, USA). Proteins were separated by SDS-PAGE and western
blotting was carried according to the standard procedures.
The following primary antibodies were used: eIF2α, JNK,
phospho-JNKThr183/Tyr185, AIF, cyclophilin D, and ANT from
Santa Cruz Biotechnology (Santa Cruz, CA, USA), GAPDH,
SERCA1, inositol-requiring enzyme 1α (IRE1α), TNF receptor
associated factor 2 (TRAF2), PERK, phospho-PERKThr980,
phospho-eIF2αSer51, activating transcription factor 4 (ATF4),
caspase 12, caspase 9, caspase 3, CHOP, and cytochrome c
from Cell Signaling Technology (Danvers, MA, USA), SERCA2,
Podocin, Nephrin, GRP78, ATF6, XBP1, voltage dependent
anion channel 1 (VDAC1), APAF1, and PPARγ from Abcam
company (Cambridge, MA, USA), phospho-IRE1αSer724 from
Novus Biologicals, SERCA3 from Proteintech Group (Chicago,
IL, USA), ASK1 from ProSci Incorporated (San Diego, CA, USA).
Secondary antibodies were horseradish peroxidase-conjugated
goat anti-rabbit IgG (BOSTER, Wuhan, China) and goat anti-
mouse IgG (BOSTER, Wuhan, China), and signals were detected
using Immobilon Western Chemiluminescent HRP Substrate
(Millipore, Billerica, MA, USA). Densitometric quantitation was
performed using Image J 1.37 software (NIH, Bethesda, MD,
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USA). Protein expression was quantified as the ratio of specific
band to GAPDH.
Quantitative RT-PCR (qRT-PCR)
Total RNAs were isolated using Trizol reagents (Invitrogen,
Carlsbad, CA, USA). First-strand cDNA was synthesized from
1 µg total RNA in a 20 µl reaction volume using a random
primer (Takara, Dalian, China) and Moloney murine leukemia
virus reverse transcriptase (New England Biolabs, Ipswich, MA,
USA). SYBR green based qRT-PCR was performed in an Applied
Biosystems ViiA 7TM real time PCR system using the following
thermal cycle reaction protocol: 50◦C for 2 min, 95◦C for 10 min,
then 40 cycles at 95◦C for 15 s, and at 60◦C for 1 min. Primers
used to amplify SERCA genes were used as previously described
(Kono et al., 2012) and synthesized by Sangon Biotech (Shanghai)
Co., Ltd. (Shanghai, China). The relative mRNA amount was
normalized to the invariant β-actin mRNA species.
SERCA Activity Measurement
Sarco/endoplasmic reticulum Ca2+-ATPase activity was
measured based on the inorganic phosphate production using
a commercially available kit (Nanjing Jiancheng Bioengineering
Institute, Nanjing, China) according to the manufacturer’s
instruction. ER fraction was obtained from the kidney using a
commercial kit (ER isolation kit, Sigma Aldrich, St. Louis, MO,
USA). Briefly, kidney tissues or podocytes were homogenized in
isotonic extraction buffer by using a glass homogenizer. After a
series of centrifugation (1,000 × g for 10 min, 12,000 × g for
15 min, and 100,000 × g for 1 h), the microsomes were obtained
and then homogenized with isotonic extraction buffer. Protein
concentration of the ER fraction was quantified and the SERCA
activities were determined.
Podocyte Treatment and Apoptosis
Assay
Conditionally immortalized mouse podocytes, kindly provided
by Prof. Niansong Wang (Shanghai Sixth People’s Hospital,
China) and originally provided by Dr. Peter Mundel (Division
of Nephrology, Massachusetts General Hospital, Harvard
University), were cultured as previously described (Mundel et al.,
1997). Differentiated podocytes were cultured in RPMI 1640
containing 1% FBS for 24 h in six-well plates (apoptosis assay)
and 10-cm dishes (protein isolation) before being exposed to
different cultural conditions. The cells were allocated into the
following groups: (1) normal control (BSA) group incubated in
RPMI 1640 containing 1% FBS and BSA, (2) palmitate group
incubated in RPMI 1640 with 1% FBS and 250 µM palmitate
complexed to BSA (palmitate medium), (3) AS-IV-treated group
pretreated with 20, 40 or 80 µM AS-IV for 12 h followed by
incubation in palmitate medium for 24 h, and (4) RGZ group
pretreated with 10 µM RGZ for 12 h followed by incubation
in palmitate medium for 24 h. AS-IV and RGZ were dissolved
in DMSO (AMRESCO, Solon, OH, USA) and the final DMSO
concentration did not exceed 0.1% (v/v). Palmitate was prepared
and podocyte apoptosis was determined by flow cytometry as
previously described (Sieber et al., 2010). In brief, a 20 mmol/L
solution of palmitic acid (Sigma, St. Louis, MO, USA) in
0.01 mol/l NaOH was complexed to 5% BSA in a molar ratio
of 8:1. Then the mixture was sterile filtrated and was added
to the serum-containing cell culture medium to achieve a
palmitic acid concentration of 250 µM. The final palmitic acid
concentration in the medium was measured using a commercial
kit (Wako Chemicals, Richmond, VA, USA). BSA was used
for control experiments and handled exactly the same as BSA
complexed to palmitic acid. Apoptotic podocytes were defined
as annexin V-positive/PI-negative (early apoptotic) and annexin
V-positive/PI-positive (late apoptotic) cells.
SERCA2b Knockdown and
Overexpression
Oligonucleotide siRNA duplex was synthesized by Invitrogen
(Carlsbad, CA, USA). The sequence of mouse SERCA2b siRNA
was 5′-GACUCUGCUUUGGAUUAUATT-3′. The sequence of
scramble siRNA was 5′-UUCUCCGAACGUGUCACGUTT-3′.
Mouse SERCA2b cDNA (GenBank accession no. AJ131821)
was synthesized and cloned into pIRES2-EGFP vector
(Addgene, Cambridge, MA, USA) to create pIRES2-EGFP-
SERCA2b plasmid (protein isolation), and then subcloned
into pcDNA3.0 vector (Invitrogen, Carlsbad, CA, USA) to
create pcDNA3.0-SERCA2b plasmid (apoptosis assay). The
transfection of siRNAs or plasmids in podocytes was carried
out with Lipofectamine R© RNAiMAX Transfection Reagent or
Lipofectamine R© 3000 Reagent (both from Invitrogen, Carlsbad,
CA, USA), respectively, according to the manufacturer’s
instruction. After being transfected with SERCA2b siRNA or
pcDNA3.0-SERCA2b/pIRES2-EGFP-SERCA2b plasmid for 24 h,
podocytes were pretreated with or without 80 µM AS-IV for 12 h
followed by incubation with 250 µM palmitate medium for 24 h
and then collected for apoptosis assay or western blotting.
Intracellular Ca2+ Concentration
Measurement
Podocytes cultured under indicated conditions were incubated
with RPMI 1640 supplemented with 2 µM Fluo-4 AM
(Invitrogen, Carlsbad, CA, USA) at 37◦C for 30 min. Then the
cells were harvested, pelleted, and suspended in ice-cold Ca2+-
free Krebs-Ringer buffer and assessed by flow cytometry (BD
FACSCalibur, Franklin Lakes, NJ, USA). The data were then
analyzed with Flowjo 7.6.1 software (FlowJo LLC, Ashland, OR,
USA).
Statistical Analysis
Data are presented as means ± SEM, with n representing the
number of animals for in vivo experiments and independent
assays for in vitro experiments. Statistical comparisons were
performed by using unpaired two-tailed t-test or one-way
ANOVA followed by the Newman–Keuls multiple comparisons
test, with P-values < 0.05 being considered significant. Statistical
analyses were conducted with Graphpad Prism software 5
software (GraphPad Software, Inc., San Diego, CA, USA). The
data and statistical analysis comply with the recommendations on
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FIGURE 1 | Effects of AS-IV on metabolic parameters in db/db mice. Eight-week-old db/db mice were treated with different doses of AS-IV for eight
consecutive weeks. (A) Body weight, (B) food intake, (C) water intake, (D) 24 h urine volume, (E) systolic blood pressure, and (F) ACR were monitored at 4-week
intervals. (G) Serum BUN and (H) serum creatinine were detected at the end of the study. Data are expressed as mean ± SEM. n = 10. ∗∗P < 0.01; #P < 0.05 and
##P < 0.01. NS, no significant difference. One-way ANOVA and Newman–Keuls multiple comparisons test (A–H).
experimental design and analysis in pharmacology (Curtis et al.,
2015).
RESULTS
AS-IV Improved Metabolic Parameters in
db/db Mice
Diabetic db/db mice had a significantly higher body weight
compared with normal db/m mice during the experiment.
However, treatment with AS-IV at 18 mg kg−1 day−1
for 8 weeks significantly reduced body weight in db/db
mice (Figure 1A). Moreover, AS-IV decreased food intake,
water intake, 24 h urine volume and hypertension in db/db
mice (Figures 1B–E). Db/db mice developed time-dependent,
progressive albuminuria (expressed as urinary ACR) and
exhibited a significant increase in BUN levels compared with
nondiabetic db/m mice. Administration of AS-IV at 6 and
18 mg kg−1 day−1 significantly ameliorated the development
of albuminuria (Figure 1F) and decreased BUN concentration
in db/db mice (Figure 1G). RGZ had striking beneficial effects
on the above parameters without altering body weight. No
significant difference in serum creatinine levels was observed
among all the groups (Figure 1H).
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FIGURE 2 | AS-IV improved glycemic control and insulin levels in db/db mice. Eight-week-old db/db mice were treated with different doses of AS-IV for eight
consecutive weeks. (A) Fasting blood glucose was recorded every 4 weeks. (B) serum HbA1c was measured at the end of the study. (C–F) Effect of AS-IV
treatment on oral glucose tolerance test in db/db and db/m mice (C) expressed as AUC (D), and on intraperitoneal insulin tolerance test in db/db and db/m mice (E)
also expressed as AUC (F). (G) Serum insulin was measured and (H) HOMA-IR was calculated after 8 weeks of intervention. Data are expressed as mean ± SEM.
n = 10. ∗∗P < 0.01; #P < 0.05 and ##P < 0.01. One-way ANOVA and Newman–Keuls multiple comparisons test (A–H).
AS-IV Improved Glucose Homeostasis
and Insulin Sensitivity in db/db Mice
The db/db mice developed hyperglycemia as confirmed by
significantly elevated fasting blood glucose (Figure 2A) and
serum HbA1c (Figure 2B), which was markedly reduced by
6 and 18 mg kg−1 day−1 AS-IV (Figures 2A,B). OGTT
experiment revealed that both 6 and 18 mg kg−1 day−1 AS-
IV-treated db/db mice exhibited enhanced glucose clearance as
demonstrated by the decreased AUC compared to db/db-vehicle
group (Figures 2C,D). IPITT showed that insulin sensitivity
was also improved significantly by 6 and 18 mg kg−1 day−1
AS-IV, confirmed by the decreases in AUC relative to
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db/db-vehicle group (Figures 2E,F). Serum insulin levels
and HOMA-IR were also significantly decreased in db/db-
6 mg kg−1·day−1 AS-IV group and db/db-18 mg kg−1·day−1 AS-
IV group compared with db/db-vehicle group (Figures 2G,H).
RGZ almost normalized the blood glucose and dramatically
improved glucose tolerance and insulin sensitivity in db/db
mice.
AS-IV Alleviated Renal Histopathology
and Inflammation in db/db Mice
Diabetic nephropathy is a chronic renal complication
accompanied by histopathologic changes in kidney (Cooper,
1998). Histological examination of the kidney revealed that
the glomerular cross-sectional area was significantly greater
in db/db mice than that in db/m mice at week 16. In addition,
db/db mice developed more severe mesangial matrix expansion
relative to their lean counterparts (Figure 3A). The 6 and
18 mg kg−1 day−1 AS-IV as well as RGZ markedly alleviated
glomerular hypertrophy and mesangial matrix expansion
(Figure 3A). Semiquantitative data further confirmed these
observations (Figures 3B–D).
Inflammation is involved in DN development
(Navarro-Gonzalez and Mora-Fernandez, 2008). The
immunohistochemistry staining revealed that MCP-1 and
TNF-α expression levels were dramatically elevated in renal
tubular epithelial cells of db/db mice compared with db/m
mice. However, AS-IV dose-dependently suppressed the
induction of MCP-1 and TNF-α (Figure 3E). Quantification
of IOD for MCP-1 and TNF-α further confirmed this
observation (Figures 3F,G). RGZ also displayed powerful
activity against renal inflammation. At week 16, kidney
weight significantly increased and the percentage of kidney
weight/body weight significantly decreased in db/db mice
relative to nondiabetic db/m mice, whereas treatment with
AS-IV or RGZ had no obvious effects on these changes
(Figures 3H,I).
AS-IV Ameliorated Podocyte Apoptosis
in db/db Mice
Podocyte apoptosis/loss is closely associated with the
pathogenesis of albuminuria and glomerulosclerosis, thus
being considered as a predictor for the progression of
DN (Reidy et al., 2014). The number of apoptotic cells
was dramatically increased in db/db mice relative to db/m
mice as demonstrated by TUNEL staining, while AS-
IV dose-dependently attenuated apoptotic cell number
(Figures 4A,B). Immunohistochemistry staining of WT-1
(podocyte nuclei) and Podocin (podocyte foot processes)
revealed marked podocyte loss in db/db mice, while AS-
IV effectively prevented the loss of podocytes (Figure 4A),
which was confirmed by semiquantitation of WT-1-
positive cells and podocin-positive area in the glomeruli
(Figures 4C,D). Western blot demonstrated that the
expression levels of Podocin and Nephrin were reduced in
renal cortex of db/db mice but was restored by AS-IV in
a dose-dependent manner (Figures 4E,F). RGZ treatment
significantly alleviated podocyte apoptosis in db/db mice
(Figure 4).
AS-IV Restored the Expression and
Activity of SERCA2 in the Kidney Cortex
of db/db Mice
To gain molecular mechanistic insights into the protective
action of AS-IV against DN, alterations in SERCA expression
were measured. qRT-PCR by using equally efficient primers
adopted by Kono et al. showed that SERCA2b was the most
prevalent mRNA species within the kidney and conditionally
immortalized mouse podocyte cell line, while both SERCA2a and
SERCA3 were expressed at extremely low levels (Figures 5A,B).
In addition, western blot results showed that SERCA2 protein
levels were significantly reduced by 50% in the renal cortex
of db/db mice relative to that of db/m controls and there
was no significant difference in SERCA3 protein levels
between db/m and db/db mice (Figures 5C,D). SERCA1
expression could not be detected (Figure 5E). Given the
qRT-PCR and western blot data, our following experiment
focused on SERCA2b isoform. The decreased SERCA2
expression in db/db mouse kidney was restored by AS-IV
in a dose-dependent manner (Figures 5F,G). In parallel to a
marked depression in SERCA2 expression, SERCA activity
was remarkably decreased by 50% in db/db mouse kidney
compared to db/m mice. However, treatment with AS-IV at
6 and 18 mg kg−1 day−1 remarkably rescued SERCA activity
in the kidneys of db/db mice (Figure 5H). RGZ significantly
prevented the reductions in SERCA2 expression and activity
(Figures 5F–H).
AS-IV Inhibited ER Stress and ER
Stress-Induced Apoptotic Pathway in the
Kidney of db/db Mice
Aberrant expression or activity of SERCA2 leads to ER Ca2+
dysregulation and triggers ER stress (Lytton et al., 1991; Park
et al., 2010; Fu et al., 2011). Immunohistochemistry staining
revealed that the expression of ER chaperone GRP78 was
dramatically up-regulated in the renal cortex of db/db mice
compared with db/m mice, which indicated the activation
of ER stress, but attenuated by AS-IV in a dose-dependent
manner (Figures 6A,B). Western blot analysis further confirmed
this observation (Figures 6C,D). Three ER stress master
regulators ATF6, PERK, IREα and their downstream targets,
such as eIF2α, ATF4, and XBP1 were activated, indicating the
activation of all three branches of UPR signaling pathway.
However, their activations were significantly suppressed by 6 and
18 mg kg−1 day−1 AS-IV treatment (Figures 6E–J). Three known
mediators of ER stress-induced apoptosis, including ATF6/PERK
downstream molecule CHOP, IRE1α downstream molecule
phospho-JNK, and cleaved caspase-12, were all enhanced in
db/db mice (Figures 6E–J). However, their expression was
remarkably reduced by AS-IV, strongly manifesting that AS-IV
abrogates ER stress and ER stress-induced apoptosis in db/db
mice.
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FIGURE 3 | AS-IV alleviated renal histopathology and renal inflammation in db/db mice. (A) Representative images of PAS staining. Scale bars, 20 µm;
Original magnification, ×400. (B) Glomerular size in each group. (C) Mesangial expansion. (D) Glomerulosclerotic score based on PAS staining. (E) Representative
images of immunohistochemistry staining for MCP-1 and TNF-α. Scale bars, 20 µm; Original magnification, ×400. (F) Quantitative result for IOD of MCP-1 in renal
cortex areas. (G) Quantitative result for IOD of TNF-α in renal cortex areas. (H) Kidney weight measurement. (I) The percentage of kidney weight/body weight. Data
are expressed as mean ± SEM. n = 6 (A–G) and n = 10 (H,I). ∗∗P < 0.01; #P < 0.05, ##P < 0.01. One-way ANOVA and Newman–Keuls multiple comparisons test
(B–D, F–I).
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FIGURE 4 | AS-IV ameliorated podocyte apoptosis in db/db mice. (A) TUNEL staining and immunohistochemistry staining for WT-1 and Podocin. Scale bars,
10 µm; Original magnification, ×400. (B) Quantification of TUNEL-positive cells in each group. Data was expressed as TUNEL-positive cell number per glomerulus.
(C) Quantification of podocyte number in each group. Results were represented as WT-1-positive podocyte number per glomerulus. (D) Quantification of the
Podocin-positive area in glomeruli. (E,F) Representative immunoblots (E) and densitometric quantification (F) of Podocin and Nephrin expression in total lysates of
kidney cortex from each group. Data are expressed as mean ± SEM. n = 6. ∗∗P < 0.01; #P < 0.05 and ##P < 0.01. One-way ANOVA and Newman–Keuls multiple
comparisons test (B–D,F).
AS-IV Suppressed
Mitochondria-Mediated Apoptotic
Pathway in the Kidney of db/db Mice
In parallel, disturbance of ER Ca2+ homeostasis by ER stress also
evokes mitochondria-mediated apoptosis. Western blot analysis
showed a decrease in anti-apoptotic protein Bcl-2 expression
and an increase in the protein levels of pro-apoptotic proteins,
such as Bax, cytochrome c, APAF1, and AIF in renal cortex of
db/db mice compared with db/m mice, while AS-IV restored their
expression (Figures 7A,B). There was no significant difference
in the expression levels of VDAC, ANT, and cyclophilin D,
components of the permeability transition pore (PTP), between
db/m mice and db/db mice (Figures 7A,C).
AS-IV Restored SERCA2 Expression and
Inhibited ER Stress-Induced Apoptosis in
Palmitate-Stimulated Podocytes
db/db mouse is an obese mouse model for type 2 diabetes,
characterized by dyslipidemia and an increase in plasma levels
of long-chain free fatty acids (FFAs) (Wahba and Mak, 2007;
Mooradian, 2009). Saturated FFAs such as palmitate are pro-
apoptotic factors and lead to podocyte apoptosis by inducing
ER stress (Martinez et al., 2008; Sieber et al., 2010). We further
confirmed the protective effect of AS-IV on ER stress-induced
apoptosis using palmitate-induced podocyte injury model
in vitro. Palmitate induced a significant podocyte apoptosis while
treatment with AS-IV significantly decreased palmitate-induced
Frontiers in Pharmacology | www.frontiersin.org 9 December 2016 | Volume 7 | Article 500
fphar-07-00500 December 19, 2016 Time: 12:27 # 10
Guo et al. AS-IV Protects Podocytes by Upregulating SERCA2
FIGURE 5 | AS-IV treatment restored SERCA2 expression and activity in the kidney of db/db mice. (A,B) qRT-PCR quantitation of SERCA2a, SERCA2b,
and SERAC3 in db/m mouse kidney cortex (A) and cultured mouse podocyte cell line (B). (C–E) Western blot analyses and densitometric quantification of SERCA2
(C), SERCA3 (D) and SERCA1 (E) levels in the lysates of kidney cortex from db/m and db/db mice. Heart and skeletal muscle lysate of db/m mice was used as
positive control. (F) The effect of AS-IV on SERCA2 expression in db/db mice determined by western blot. (G) Densitometric quantification of SERCA2 expression in
the kidney cortex lysates from each group. (H) Relative SERCA2 activity in ER extraction of the kidney from each group. ∗∗P < 0.01; ##P < 0.01. NS, no significant
difference. Data are expressed as mean ± SEM. n = 6. Student’s t-test (A–D), one-way ANOVA and Newman–Keuls multiple comparisons test (G,H).
podocyte apoptosis in a concentration-dependent manner,
manifested by flow cytometric analysis (Figures 8A,B). Podocin
expression was significantly downregulated in palmitate-
stimulated podocytes, accompanied with a dramatic reduction
in SERCA2 expression and activity and an increase in GRP78
expression. However, AS-IV markedly restored Podocin
expression as well as SERCA2 expression and activity, and
GPR78 expression was significantly attenuated at the same
time (Figures 8C–E). Further study showed that AS-IV
suppressed the activation of three UPR arms including ATF6,
PERK-eIF-2α-ATF4, and IRE1α-XBP1 (Figures 8F–I). ER
stress-mediated apoptotic pathway was activated by palmitate
but inhibited by AS-IV, as manifested by the down-regulation
of CHOP, TRAF2, ASK1, phospho-JNK and cleaved caspase
12 in AS-IV treated group relative to those in palmitate group
(Figures 8F–K).
AS-IV Restored Ca2+ Homeostasis and
Suppressed Mitochondria-Mediated
Apoptotic Pathway in
Palmitate-Stimulated Podocytes
Consistent with a decrease in SERCA2 expression and activity,
palmitate resulted in a rise in basal cytosolic Ca2+ levels. AS-IV
restored basal cytosolic Ca2+ levels in a dose-dependent manner
(Figures 9A,B). Meanwhile, palmitate induced the expression
of cytochrome c, APAF1 and AIF in podocytes, suggesting
the activation of mitochondria-mediated apoptotic pathway.
However, the induction of cytochrome c, APAF1, and AIF was
markedly suppressed by AS-IV in a dose-dependent manner. The
expression levels of PTP proteins, including VDAC, Cyclophilin
D, and ANT, were not significantly changed under different
cultural conditions (Figures 9C–E).
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FIGURE 6 | AS-IV attenuated ER stress and ER stress-induced apoptotic pathway in the kidney of db/db mice. (A,B) Representative pictures for GRP78
immunohistochemistry staining (A) and quantification of IOD (B) for GRP78 in each group. Scale bars, 10 µm; Original magnification, ×400. (C,D) Western blot
analyses (C) and densitometric quantification (D) of GRP78 expression in the kidney cortex lysates from each group. (E,F) Representative immunoblots (E) and
densitometric quantification (F) of ATF6, p-PERK, p-eIF2α, ATF4, CHOP expression in total lysates of kidney cortex from each group. (G,H) Representative
immunoblots (G) and densitometric quantification (H) of p-IRE1α, spliced-XBP1, TRAF2, ASK1, and phospho-JNKThr183/Tyr185 expression in total lysates of kidney
cortex from each group. (I,J) Representative immunoblots (I) and densitometric quantification (J) of cleaved caspase 12, cleaved caspase 9 and cleaved caspase 3
expression in total lysates of kidney cortex from each group. Data are expressed as mean ± SEM. n = 6. ∗∗P < 0.01; #P < 0.05 and ##P < 0.01. One-way ANOVA
and Newman–Keuls multiple comparisons test (B,D,F,H,J).
AS-IV Attenuated Palmitate-Induced
Podocyte Apoptosis by Regulating
SERCA2b Expression
To further confirm the role of SERCA2b in mediating the
effect of AS-IV on ER stress-induced podocyte apoptosis,
we knocked down endogenous SERCA2b expression using
a SERCA2b-specific siRNA or overexpressed the exogenous
SERCA2b by transfection with SERCA2b overexpression
plasmid. SERCA2 expression was reduced by 70% after
SERCA2b siRNA transfection (Figure 10A) and increased
significantly after SERCA2b overexpression plasmid transfection
(Figure 10B). We then transfected SERCA2b siRNA or SERCA2
overexpression plasmid into podocytes to investigate the role
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FIGURE 7 | Effects of AS-IV on mitochondrial-mediated apoptotic pathway in the kidney of db/db mice. (A) Representative immunoblots showing Bcl-2,
Bax, cytochrome c, APAF1, AIF and the permeability transition pore (PTP) protein levels in renal cortex lysates obtained from each group. (B) Quantification of Bcl-2,
Bax, cytochrome c, APAF1, AIF expression showed in panel A. (C) Quantification of PTP protein expression showed in panel A. Data are expressed as
mean ± SEM. n = 6. ∗∗P < 0.01; #P < 0.05, ##P < 0.01. One-way ANOVA and Newman–Keuls multiple comparisons test (B,C).
of SERCA2b in the action of AS-IV. Flow cytometric analysis
showed that SERCA2b knockdown resulted in a significant
increase in palmitate-induced apoptosis and abolished the
protective effect of AS-IV on podocytes, while SERCA2b
overexpression significantly decreased palmitate-induced
apoptosis and achieved a similar beneficial effect as AS-IV
on podocytes (Figures 10C,D). Further data showed that
SERCA2b knockdown markedly increased palmitate-induced
intracellular Ca2+ rise and ER stress, enhanced the activation
of ER stress-mediated apoptotic pathway and blocked the
inhibitory effect of AS-IV on palmitate-induced intracellular
Ca2+ alteration and ER stress, while SERCA2b overexpression
significantly attenuated palmitate-induced intracellular Ca2+
rise and ER stress, repressed the activation of ER stress-mediated
apoptotic pathway, and achieved a similar potential as AS-IV on
intracellular Ca2+ dysregulation and ER stress (Figures 10E–I).
DISCUSSION
In the present study, with db/db mice, a model of spontaneous
DN from type 2 diabetes, we confirmed the pronounced
protective effect of AS-IV against DN. Importantly, we found
a significant reduction of SERCA2 expression and activity in
db/db mouse kidney and cultured mouse podocytes exposed
to palmitate, accompanied by an increase of cytosolic Ca2+
levels, an induction of ER stress and the activation of
three UPR pathways, ER stress-mediated apoptotic pathway
and mitochondria-mediated apoptotic pathway, which lead to
podocyte apoptosis in vivo and in vitro. However, AS-IV restored
SERCA2 expression, rescued intracellular Ca2+ homeostasis,
and reversed the activation of UPR and ER stress-mediated
apoptotic pathway as well as mitochondria-mediated apoptotic
pathway, concomitant with a marked attenuation of podocyte
apoptosis in vivo and in vitro. Further study revealed that
SERCA2b knockdown abolished the inhibitory effect of AS-
IV on ER stress-induced apoptotic pathway, while SERCA2b
overexpression exhibited an anti-apoptotic action. Our data
suggest that the beneficial effect of AS-IV on DN is associated
with the alleviation of ER stress via upregulating SERCA2
expression, which subsequently alleviates ER stress-induced
podocyte apoptosis, thereby preventing the development of DN.
The SERCA pump is responsible for maintaining ER
Ca2+ homeostasis and serves as an essential gatekeeper for
ER function (Vangheluwe et al., 2005). Recently, SERCA
dysfunction has been linked with experimental and human
pathology, including heart failure (Shareef et al., 2014), diabetes
(Zarain-Herzberg et al., 2014), vascular diseases (Adachi et al.,
2004; Davies, 2015), tumor (Wang et al., 2011), as well as
muscular dystrophy (Gehrig et al., 2012; Schneider et al.,
2013). Of all the SERCA isoforms, SERCA2b is ubiquitously
expressed and considered the housekeeping isoform, while
SERCA2a is a muscle-specific isoform expressed in type I
(slow) skeletal, cardiac, and smooth muscle (Vangheluwe et al.,
2005). SERCA1 is restricted to fast-twitch skeletal muscle
and SERCA3 is present in a limited number of nonmuscle
cells including platelets and endothelial cells (Vangheluwe
et al., 2005). Here, we identified SERCA2b as the most
highly expressed isoform at transcriptional level in both mouse
kidney cortex and conditionally immortalized mouse podocyte
cell line, whereas SERCA2a and SERCA3 were expressed at
very low levels (Figure 5). We detected no expression of
SERCA1. Therefore, our following study focused on SERCA2b
isoform.
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FIGURE 8 | AS-IV restored SERCA2 expression and inhibited ER stress-mediated apoptosis in palmitate-stimulated podocytes. Podocytes were
pretreated with or without AS-IV at the indicated concentrations (20, 40, and 80 µM respectively) for 12 h followed by 250 µM palmitate exposure for 24h.
(A) Representative flow cytometry results for podocytes under different cultural conditions. (B) Semiquantitative data showing percentage of apoptotic podocytes
under different cultural conditions. (C,D) Representative immunoblots (C) and quantification (D) of Podocin, SERCA2 and GRP78 under different conditions.
(E) SERCA activity under different conditions. (F,G) Representative immunoblots (F) and quantification (G) of key molecules in
ATF6-CHOP/PERK–eIF-2α–ATF4–CHOP signaling pathways under different conditions. (H,I) Representative immunoblots (H) and quantification (I) of key molecules
in IRE1–XBP1/IRE1-TRAF2–ASK1–JNK signaling pathway. (J,K) Representative immunoblots (J) and quantification (K) of cleaved caspase 12 and cleaved caspase
3 under different conditions. Data are expressed as mean ± SEM. n = 3–5. ∗∗P < 0.01; #P < 0.05 and ##P < 0.01. One-way ANOVA and Newman–Keuls multiple
comparisons test (B,D,E,G,I,K).
The link between SERCA dysfunction and ER stress has
been well established. Thapsigargin, an inhibitor of SERCA,
abolishes Ca2+ uptake into the ER, leading to ER stress
and subsequent initiation of UPR (Lytton et al., 1991).
Several groups have revealed that SERCA2 activity and/or
expression is reduced in metabolic syndrome, and the reduction
results in ER stress and ER stress-induced apoptosis. The
restoration of SERCA2 activity or expression can ameliorate
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FIGURE 9 | AS-IV normalized intracellular Ca2+ levels and suppressed mitochondria-mediated apoptotic pathway in palmitate-stimulated
podocytes. Podocytes were pretreated with or without AS-IV at the indicated concentrations (20, 40, and 80 µM, respectively) for 12 h followed by 250 µM
palmitate incubation for 24 h. (A) Representative pictures of Fluo-4 AM staining showing intracellular Ca2+ levels under different conditions. (B) The relative fluo-4
AM fluorescence intensity under different conditions. (C) Representative immunoblots for cytochrome c, APAF1, AIF, and the PTP protein levels in podocytes under
different conditions. (D) Quantification of cytochrome c, APAF1, AIF expression in podocytes under different conditions. (E) Quantification of the PTP protein
expression levels in podocytes under different conditions. Data are expressed as mean ± SEM. n = 3–5. ∗∗P < 0.01; #P < 0.05 and ##P < 0.01. One-way ANOVA
and Newman–Keuls multiple comparisons test (B,D,E).
ER stress and in turn improve metabolic abnormalities (Park
et al., 2010; Kang et al., 2015). SERCA2b in diabetic islet
is downregulated, resulting in Ca2+ dysregulation, insulin-
secretory defects and ER stress, while restoration of islet SERCA2
levels by pioglitazone, the agonist of PPARγ, reduces ER
stress and enhances islet function (Evans-Molina et al., 2009;
Kono et al., 2012). SERCA2b protein and mRNA levels are
dramatically reduced in the liver of ob/ob mice accompanied
by the increased ER stress and apoptosis, and overexpressed
SERCA2b or pharmacologically activated SERCA2b in the liver
of obese and diabetic mice improves glucose homeostasis,
reduces steatohepatitis, and inhibits ER stress and ER stress-
induced apoptosis via ameliorating PERK/eIF2α/CHOP and
IRE1α/JNK/XBP1 pathways (Park et al., 2010; Kang et al., 2015).
In hearts of OLETF, a rat model of type 2 diabetes, SERCA2a
protein is reduced and this reduction was restored by treatment
with 4-phenyl butyric acid (PBA), an ER stress inhibitor
(Takada et al., 2012). Impaired SERCA activity contributes to
cardiomyocyte dysfunction in insulin resistant rats (Wold et al.,
2005). All the above reports highlight a potential pathological
role for SERCA2 in the development of metabolic syndrome.
In the present study, we found that SERCA2 expression and
SERCA activity were significantly decreased in the kidney cortex
of db/db mice (Figure 5) and mouse podocytes incubated with
palmitate (Figure 8), paralleled by an elevation of intracellular
Ca2+ levels in palmitate-incubated podocytes (Figure 9), an
induction of ER stress and the activation of three UPR arms as
well as ER stress-mediated apoptotic pathway as evidenced by
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FIGURE 10 | SERCA2 mediated the inhibitory effect of AS-IV on palmitate-induced podocyte apoptosis. Podocytes were transfected with scramble siRNA
(siNC), specific SERCA2b siRNA (siSERCA2b), empty vector and SERCA2b overexpression (ov.) plasmid, respectively, for 24 h, and then pretreated with or without
80 µM AS-IV for 12 h followed by stimulation with 250 µM palmitate for 24 h. (A) Western blot and densitometric quantification of the endogenous SERCA2b
expression in podocytes transfected with siSERCA2b or siNC. (B) Western blot and densitometric quantification of the total SERCA2b expression in podocytes
transfected with SERCA2b ov. plasmid or empty vector. (C,D) Representative flow cytometry results (C) and semiquantitative data (D) for podocyte apoptosis under
different cultural conditions. (E) Representative picture of Fluo-4 AM staining showing intracellular Ca2+ levels under different conditions. (F) The relative fluo-4 AM
fluorescence intensity depicting intracellular Ca2+ levels under different conditions. (G–I) Representative immunoblots (G) and quantification (H,I) of SERCA2 and ER
stress-associated proteins under different conditions. Data are expressed as mean ± SEM. n = 3–5. ∗∗P < 0.01; #P < 0.05 and ##P < 0.01. NS, no significant
difference. Student’s t-test (A,B), one-way ANOVA and Newman–Keuls multiple comparisons test (D,F,H,I).
increased expression of GRP78, cleaved ATF6, phospho-PERK,
phospho-eIF2α, ATF4, CHOP, phospho-IRE1α, spliced XBP1,
ASK1, TRAF2, phospho-JNK, and cleaved caspase 12 (Figures 6
and 8). However, the increases in cytosolic Ca2+ levels and the
induction of ER stress indicators were inhibited by AS-IV in a
dose-dependent manner along with the restoration of SERCA2
expression and SERCA activity in vivo and in vitro (Figures 5,
8, and 9). Further study revealed that knockdown of SERCA2
enhanced palmitate-induced intracellular Ca2+ rise, aggravated
palmitate-induced ER stress and blunted SERCA2b up-regulation
by AS-IV, while SERCA2 overexpression diminished palmitate-
induced intracellular Ca2+ rise, alleviated ER stress and
prevented the initiation of UPR with a similar potency achieved
by AS-IV. Meanwhile, SERCA2b knockdown blocked the
inhibitory effect of AS-IV on intracellular Ca2+ dysregulation, ER
stress and ER stress-mediated apoptotic pathway while SERCA2
overexpression exhibited an opposite effect (Figure 10). These
data strongly provide evidence that AS-IV suppresses ER stress
at least in part through upregulating SERCA2b expression. In
parallel with the upregulation of CHOP, phospho-JNK and
cleaved caspase 12, positive indicators of ER stress-mediated
apoptotic pathway, podocyte apoptosis was significantly induced
but markedly attenuated by AS-IV in vivo and in vitro (Figures 4
and 8). The findings are in agreement with recent reports that ER
stress plays an important role in podocyte apoptosis (Sieber et al.,
2010; Cao et al., 2016) and AS-IV has pharmacological activities
against podocyte injury through ER stress inhibition (Chen Y.
et al., 2014; Wang et al., 2015).
Endoplasmic reticulum and mitochondria are physiologically
and functionally interacted, with calcium signaling being
the hub of the interaction between the two organelles.
Recent studies demonstrated that disruption of ER Ca2+
homeostasis contributes to apoptosis through mitochondria-
mediated apoptotic pathway. Enhanced mitochondria uptake
of Ca2+ released from the ER leads to the release of pro-
apoptotic factors such as cytochrome c, smac/Diablo, and AIF.
Cytochrome c then binds to APAF1, leading to the cleavage of
procaspase 9 into active caspase 9 and subsequent activation
of caspase 3 (Malhotra and Kaufman, 2011). In our study,
mitochondria-mediated apoptotic pathway was evoked in db/db
mice and palmitate-stimulated podocytes, confirmed by elevated
expression of cytochrome c, APAF1 and AIF, but the induction of
these proteins was significantly attenuated by AS-IV (Figures 7
and 9). In aggregate, AS-IV attenuated ER stress-induced
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podocyte apoptosis probably through simultaneous inhibition of
both ER stress-mediated apoptotic pathway and mitochondria-
mediated apoptotic pathway.
Remarkably, the renoprotective effect of AS-IV-dependent
SERCA2 restoration was confirmed in db/db mice. Treatment
with AS-IV at 18 mg kg−1 day−1 for 8 weeks significantly
reduced body weight gain associated with the decreases in food
consumption, water intake and 24 h urine volume in db/db
mice during the whole experiment (Figure 1). Besides, AS-
IV improved renal function of db/db mice as manifested by
reduced albuminuria and serum BUN levels (Figure 1). Serum
creatinine levels were not changed significantly, probably due to
that 16-week-old db/db mice are in the early stage of DN and
serum creatinine concentration has not increased significantly
yet (Kaizu and Komine, 2001). SERCA2 restoration by AS-IV
improved glucose homeostasis in db/db mice, as confirmed by
the lowered blood glucose and the improved glucose tolerance
and insulin sensitivity (Figure 2). This is indeed consistent
with the previous reports that SERCA2b overexpression or
SERCA2b activation can improve glucose homeostasis in diabetic
ob/ob mice (Park et al., 2010; Kang et al., 2015) and that
cardiac-specific SERCA overexpression improves whole body
glucose homeostasis by rescuing diabetes induced-alterations
in cardiac glucose transport (Waller et al., 2015). Moreover,
AS-IV attenuated glomerular hypertrophy, mesangial matrix
expansion, and renal inflammation in a dose-dependent manner
in db/db mice (Figure 3). All these observations demonstrate a
pronounced renoprotective effect of AS-IV against DN. Though
it is unclear whether the improved renal function is the direct
effect of AS-IV on podocytes or the indirect effect of improved
metabolic milieu of type 2 diabetes such as improved glycemic
control, or a combination of both effects, the in vitro studies
do at least help define that AS-IV had direct protective action
on podocytes under diabetic conditions. It is noteworthy that
lean db/m mice treated with AS-IV did not exhibited any
obvious alterations in either metabolic homeostasis or histology,
indicating that AS-IV is unlikely to induce abnormalities in
metabolically healthy animals.
Thiazolidinedione drugs, such as RGZ or pioglitazone,
agonists of PPARγ, are used to treat type 2 diabetes by improving
insulin sensitivity (Campbell, 2005). There are accumulating
evidence of diverse effects of PPARγ agonists on podocytes
and DN progression (Benigni et al., 2006; Kanjanabuch et al.,
2007). In our study, RGZ significantly normalized metabolic
and biochemical parameters and preserved renal function in
db/db mice. Furthermore, PPARγ expression was downregulated
in renal cortex of diabetic db/db mice and palmitate-incubated
podocytes. Both AS-IV and RGZ could restored PPARγ
expression (Supplementary Figures 1 and 2C,D), which was
consistent with the recent finding that AS-IV is a novel natural
PPARγ agonist (Wang et al., 2016). PPARγ was identified as a
direct transcriptional regulator of the SERCA2 gene in β-cells
under diabetic conditions (Kono et al., 2012). Similarly, we
found that AS-IV and RGZ improved SERCA2 expression in
palmitate-incubated podocytes (Supplementary Figures 2C,D),
which raises the attractive possibility that SERCA2 is a direct
downstream target for PPARγ since SERCA genes contain
conserved PPAR-responsive elements within their regulatory
regions (Zarain-Herzberg and Alvarez-Fernandez, 2002). In
addition, RGZ rescued intracellular Ca2+ homeostasis, mitigated
ER stress and exhibited cytoprotection against palmitate-induced
podocyte apoptosis (Supplementary Figures 2 and 3). Thus, we
propose that AS-IV may act as a PPARγ agonist and mitigate
ER stress in podocytes by a mechanism involving at least
SERCA activity, but further studies are still needed to clarify the
mechanism.
CONCLUSION
Our current study has suggested for the first time that the
improvement of SERCA2 expression and function by AS-IV
prevents the progression of DN in db/db mice. The restoration of
SERCA2 expression is associated with concomitant restoration of
intracellular Ca2+ homeostasis and enhancement of ER function,
which attenuate ER stress and subsequently relieve ER stress-
induced podocyte apoptosis, finally inhibiting the progression
of DN. We provide evidence that AS-IV may be a novel
therapeutic agent modulating SERCA2b expression to prevent
the development of DN.
ETHICS STATEMENT
All the work was carried out in accordance with the approved
guidelines for the use of experimental animals in Putuo Hospital,
Shanghai University of Traditional Chinese Medicine.
AUTHOR CONTRIBUTIONS
HG and AC designed the study, performed part of experiments,
interpreted the data and performed data analysis. SC, YiW, YZ,
XM, and CL performed part of experiments. HW, YuW, XZ, and
WP interpreted the data, drafted the manuscript and revised it
critically for intellectual content. All authors read and approved
the final version of the manuscript before submission.
ACKNOWLEDGMENTS
This study was supported by the National Natural Science
Foundation of China (81473480), the Talent Project of Integrative
Medicine of Shanghai Municipal Health Bureau (ZYSNXD012-
RC-ZXY), Key Medical Discipline Project of Shanghai Municipal
Health Bureau (ZK2015A18), the Innovation Program of Talent
Project of Putuo District (2014-A-19), and the Leading Academic
Discipline Project of State Administration of Traditional Chinese
Medicine of China.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at: http://journal.frontiersin.org/article/10.3389/fphar.2016.
00500/full#supplementary-material
Frontiers in Pharmacology | www.frontiersin.org 16 December 2016 | Volume 7 | Article 500
fphar-07-00500 December 19, 2016 Time: 12:27 # 17
Guo et al. AS-IV Protects Podocytes by Upregulating SERCA2
REFERENCES
Adachi, T., Weisbrod, R. M., Pimentel, D. R., Ying, J., Sharov, V. S., Schoneich, C.,
et al. (2004). S-Glutathiolation by peroxynitrite activates SERCA during arterial
relaxation by nitric oxide. Nat. Med. 10, 1200–1207. doi: 10.1038/nm1119
Ashby, M. C., and Tepikin, A. V. (2001). ER calcium and the functions of
intracellular organelles. Semin. Cell Dev. Biol. 12, 11–17. doi: 10.1006/scdb.2000.
0212
Benigni, A., Zoja, C., Tomasoni, S., Campana, M., Corna, D., Zanchi, C., et al.
(2006). Transcriptional regulation of nephrin gene by peroxisome proliferator-
activated receptor-gamma agonist: molecular mechanism of the antiproteinuric
effect of pioglitazone. J. Am. Soc. Nephrol. 17, 1624–1632. doi: 10.1681/ASN.
2005090983
Campbell, I. W. (2005). The clinical significance of PPAR gamma agonism. Curr.
Mol. Med. 5, 349–363. doi: 10.2174/1566524053766068
Cao, A. L., Wang, L., Chen, X., Wang, Y. M., Guo, H. J., Chu, S., et al. (2016).
Ursodeoxycholic acid and 4-phenylbutyrate prevent endoplasmic reticulum
stress-induced podocyte apoptosis in diabetic nephropathy. Lab. Invest. 96,
610–622. doi: 10.1038/labinvest.2016.44
Cardozo, A. K., Ortis, F., Storling, J., Feng, Y. M., Rasschaert, J., Tonnesen, M., et al.
(2005). Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+
ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of
endoplasmic reticulum stress in pancreatic beta-cells. Diabetes 54, 452–461.
Chen, J., Chen, Y., Luo, Y., Gui, D., Huang, J., and He, D. (2014a). Astragaloside
IV ameliorates diabetic nephropathy involving protection of podocytes in
streptozotocin induced diabetic rats. Eur. J. Pharmacol 736, 86–94. doi: 10.1016/
j.ejphar.2014.04.037
Chen, J., Liang, L., Zhan, L., Zhou, Y., Zheng, L., Sun, X., et al. (2014b). ZiBuPiYin
recipe protects db/db mice from diabetes-associated cognitive decline through
improving multiple pathological changes. PLoS ONE 9:e91680. doi: 10.1371/
journal.pone.0091680
Chen, Y., Gui, D., Chen, J., He, D., Luo, Y., and Wang, N. (2014). Down-
regulation of PERK-ATF4-CHOP pathway by Astragaloside IV is associated
with the inhibition of endoplasmic reticulum stress-induced podocyte apoptosis
in diabetic rats. Cell Physiol. Biochem. 33, 1975–1987. doi: 10.1159/0003
62974
Chen, Y., Liu, C. P., Xu, K. F., Mao, X. D., Lu, Y. B., Fang, L., et al.
(2008). Effect of taurine-conjugated ursodeoxycholic acid on endoplasmic
reticulum stress and apoptosis induced by advanced glycation end products in
cultured mouse podocytes. Am. J. Nephrol. 28, 1014–1022. doi: 10.1159/0001
48209
Cooper, M. E. (1998). Pathogenesis, prevention, and treatment of diabetic
nephropathy. Lancet 352, 213–219. doi: 10.1016/S0140-6736(98)01346-4
Curtis, M. J., Bond, R. A., Spina, D., Ahluwalia, A., Alexander, S. P., Giembycz,
M. A., et al. (2015). Experimental design and analysis and their reporting:
new guidance for publication in BJP. Br. J. Pharmacol. 172, 3461–3471. doi:
10.1111/bph.12856
Davies, M. G. (2015). New insights on the role of SERCA during vessel remodeling
in metabolic syndrome. Diabetes 64, 3066–3068. doi: 10.2337/db15-0761
Evans-Molina, C., Robbins, R. D., Kono, T., Tersey, S. A., Vestermark, G. L.,
Nunemaker, C. S., et al. (2009). Peroxisome proliferator-activated receptor
gamma activation restores islet function in diabetic mice through reduction of
endoplasmic reticulum stress and maintenance of euchromatin structure. Mol.
Cell. Biol. 29, 2053–2067. doi: 10.1128/MCB.01179-08
Fu, S., Yang, L., Li, P., Hofmann, O., Dicker, L., Hide, W., et al. (2011). Aberrant
lipid metabolism disrupts calcium homeostasis causing liver endoplasmic
reticulum stress in obesity. Nature 473, 528–531. doi: 10.1038/nature09968
Gehrig, S. M., van der Poel, C., Sayer, T. A., Schertzer, J. D., Henstridge, D. C.,
Church, J. E., et al. (2012). Hsp72 preserves muscle function and slows
progression of severe muscular dystrophy. Nature 484, 394–398. doi: 10.1038/
nature10980
Gui, D., Guo, Y., Wang, F., Liu, W., Chen, J., Chen, Y., et al. (2012). Astragaloside
IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro
and in vivo. PLoS ONE 7:e39824. doi: 10.1371/journal.pone.0039824
Gui, D., Huang, J., Guo, Y., Chen, J., Chen, Y., Xiao, W., et al. (2013). Astragaloside
IV ameliorates renal injury in streptozotocin-induced diabetic rats through
inhibiting NF-kappaB-mediated inflammatory genes expression. Cytokine 61,
970–977. doi: 10.1016/j.cyto.2013.01.008
He, Q., Pu, J., Yuan, A., Yao, T., Ying, X., Zhao, Y., et al. (2014). Liver X receptor
agonist treatment attenuates cardiac dysfunction in type 2 diabetic db/db mice.
Cardiovasc. Diabetol. 13, 149. doi: 10.1186/s12933-014-0149-0
Inagi, R. (2010). Endoplasmic reticulum stress as a progression factor for kidney
injury. Curr. Opin. Pharmacol. 10, 156–165. doi: 10.1016/j.coph.2009.11.006
Inagi, R., Ishimoto, Y., and Nangaku, M. (2014). Proteostasis in endoplasmic
reticulum–new mechanisms in kidney disease. Nat. Rev. Nephrol. 10, 369–378.
doi: 10.1038/nrneph.2014.67
Kaizu, K., and Komine, N. (2001). [Diabetic nephropathy; clinical stage and
prediction]. Rinsho Byori 49, 1205–1211.
Kang, S., Dahl, R., Hsieh, W., Shin, A. C., Zsebo, K. M., Buettner, C., et al. (2015).
Small molecular allosteric activator of the sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA) attenuates diabetes and metabolic disorders. J. Biol. Chem.
291, 5185–5198. doi: 10.1074/jbc.M115.705012
Kanjanabuch, T., Ma, L. J., Chen, J., Pozzi, A., Guan, Y., Mundel, P., et al.
(2007). PPAR-gamma agonist protects podocytes from injury. Kidney Int. 71,
1232–1239. doi: 10.1038/sj.ki.5002248
Kono, T., Ahn, G., Moss, D. R., Gann, L., Zarain-Herzberg, A., Nishiki, Y., et al.
(2012). PPAR-gamma activation restores pancreatic islet SERCA2 levels and
prevents beta-cell dysfunction under conditions of hyperglycemic and cytokine
stress. Mol. Endocrinol. 26, 257–271. doi: 10.1210/me.2011-1181
Lytton, J., Westlin, M., and Hanley, M. R. (1991). Thapsigargin inhibits the
sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps.
J. Biol. Chem. 266, 17067–17071.
Malhotra, J. D., and Kaufman, R. J. (2011). ER stress and its functional link to
mitochondria: role in cell survival and death. Cold Spring Harb. Perspect. Biol.
3, a004424. doi: 10.1101/cshperspect.a004424
Martinez, S. C., Tanabe, K., Cras-Meneur, C., Abumrad, N. A., Bernal-Mizrachi, E.,
and Permutt, M. A. (2008). Inhibition of Foxo1 protects pancreatic islet beta-
cells against fatty acid and endoplasmic reticulum stress-induced apoptosis.
Diabetes Metab. Res. Rev. 57, 846–859. doi: 10.2337/db07-0595
Mooradian, A. D. (2009). Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract.
Endocrinol. Metab. 5, 150–159. doi: 10.1038/ncpendmet1066
Mundel, P., Reiser, J., Zuniga Mejia Borja, A., Pavenstadt, H., Davidson, G. R.,
Kriz, W., et al. (1997). Rearrangements of the cytoskeleton and cell contacts
induce process formation during differentiation of conditionally immortalized
mouse podocyte cell lines. Exp. Cell Res. 236, 248–258. doi: 10.1006/excr.1997.
3739
Navarro-Gonzalez, J. F., and Mora-Fernandez, C. (2008). The role of inflammatory
cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 433–442. doi: 10.
1681/ASN.2007091048
Ozcan, L., and Tabas, I. (2012). Role of endoplasmic reticulum stress in metabolic
disease and other disorders. Annu. Rev. Med. 63, 317–328. doi: 10.1146/
annurev-med-043010-144749
Ozcan, U., Yilmaz, E., Ozcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., et al.
(2006). Chemical chaperones reduce ER stress and restore glucose homeostasis
in a mouse model of type 2 diabetes. Science 313, 1137–1140. doi: 10.1126/
science.1128294
Park, S. W., Zhou, Y., Lee, J., Lee, J., and Ozcan, U. (2010). Sarco(endo)plasmic
reticulum Ca2+-ATPase 2b is a major regulator of endoplasmic reticulum
stress and glucose homeostasis in obesity. Proc. Natl. Acad. Sci. U.S.A. 107,
19320–19325. doi: 10.1073/pnas.1012044107
Peng, A., Gu, Y., Gui, D. K., Zhu, Q. Y., Zhu, K. Y., and Lin, S. Y. (2008). Aqueous
extract of astragali Radix induces human natriuresis through enhancement of
renal response to atrial natriuretic peptide. J. Ethnopharmacol. 116, 413–421.
doi: 10.1016/j.jep.2007.12.005
Qi, W., Mu, J., Luo, Z. F., Zeng, W., Guo, Y. H., Pang, Q., et al. (2011). Attenuation
of diabetic nephropathy in diabetes rats induced by streptozotocin by regulating
the endoplasmic reticulum stress inflammatory response. Metabolism 60, 594–
603. doi: 10.1016/j.metabol.2010.07.021
Reagan-Shaw, S., Nihal, M., and Ahmad, N. (2008). Dose translation from animal
to human studies revisited. FASEB J. 22, 659–661. doi: 10.1096/fj.07-9574LSF
Reidy, K., Kang, H. M., Hostetter, T., and Susztak, K. (2014). Molecular
mechanisms of diabetic kidney disease. J. Clin. Invest. 124, 2333–2340. doi:
10.1172/JCI72271
Rios, J. L., and Waterman, P. G. (1997). A review of the pharmacology and
toxicology of Astragalus. Phytother. Res. 11, 411–418. doi: 10.1002/(SICI)1099-
1573(199709)11:6<411::AID-PTR132>3.0.CO;2-6
Frontiers in Pharmacology | www.frontiersin.org 17 December 2016 | Volume 7 | Article 500
fphar-07-00500 December 19, 2016 Time: 12:27 # 18
Guo et al. AS-IV Protects Podocytes by Upregulating SERCA2
Ron, D., and Walter, P. (2007). Signal integration in the endoplasmic reticulum
unfolded protein response. Nat. Rev. Mol. Cell Biol. 8, 519–529. doi: 10.1038/
nrm2199
Schneider, J. S., Shanmugam, M., Gonzalez, J. P., Lopez, H., Gordan, R.,
Fraidenraich, D., et al. (2013). Increased sarcolipin expression and decreased
sarco(endo)plasmic reticulum Ca2+ uptake in skeletal muscles of mouse
models of Duchenne muscular dystrophy. J. Muscle Res. Cell Motil. 34, 349–356.
doi: 10.1007/s10974-013-9350-0
Shareef, M. A., Anwer, L. A., and Poizat, C. (2014). Cardiac SERCA2A/B:
therapeutic targets for heart failure. Eur. J. Pharmacol 724, 1–8. doi: 10.1016/
j.ejphar.2013.12.018
Sharma, K., McCue, P., and Dunn, S. R. (2003). Diabetic kidney disease in the db/db
mouse. Am. J. Physiol. Renal Physiol. 284, F1138–F1144. doi: 10.1152/ajprenal.
00315.2002
Sieber, J., Lindenmeyer, M. T., Kampe, K., Campbell, K. N., Cohen, C. D.,
Hopfer, H., et al. (2010). Regulation of podocyte survival and endoplasmic
reticulum stress by fatty acids. Am. J. Physiol. Renal Physiol. 299, F821–F829.
doi: 10.1152/ajprenal.00196.2010
Takada, A., Miki, T., Kuno, A., Kouzu, H., Sunaga, D., Itoh, T., et al. (2012). Role
of ER stress in ventricular contractile dysfunction in type 2 diabetes. PLoS ONE
7:e39893. doi: 10.1371/journal.pone.0039893
Taneda, S., Pippin, J. W., Sage, E. H., Hudkins, K. L., Takeuchi, Y., Couser, W. G.,
et al. (2003). Amelioration of diabetic nephropathy in SPARC-null mice. J. Am.
Soc. Nephrol. 14, 968–980. doi: 10.1097/01.ASN.0000054498.83125.90
Tesch, G. H., and Lim, A. K.-H. (2011). Recent insights into diabetic renal injury
from the db/db mouse model of type 2 diabetic nephropathy. Am. J. Physiol.
Renal Physiol. 300, F301–F310. doi: 10.1152/ajprenal.00607.2010
Vangheluwe, P., Raeymaekers, L., Dode, L., and Wuytack, F. (2005). Modulating
sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell
biological implications. Cell Calcium 38, 291–302. doi: 10.1016/j.ceca.2005.06.
033
Wahba, I. M., and Mak, R. H. (2007). Obesity and obesity-initiated metabolic
syndrome: mechanistic links to chronic kidney disease. Clin. J. Am. Soc.
Nephrol. 2, 550–562. doi: 10.2215/CJN.04071206
Waller, A. P., Kalyanasundaram, A., Hayes, S., Periasamy, M., and Lacombe, V. A.
(2015). Sarcoplasmic reticulum Ca2+ ATPase pump is a major regulator of
glucose transport in the healthy and diabetic heart. Biochim. Biophys. Acta 1852,
873–881. doi: 10.1016/j.bbadis.2015.01.009
Wang, C., Chen, Z., Li, S., Zhang, Y., Jia, S., Li, J., et al. (2014). Hepatic
overexpression of ATP synthase beta subunit activates PI3K/Akt pathway
to ameliorate hyperglycemia of diabetic mice. Diabetes Metab. Res. Rev 63,
947–959. doi: 10.2337/db13-1096
Wang, L., Chi, Y. F., Yuan, Z. T., Zhou, W. C., Yin, P. H., Zhang, X. M.,
et al. (2014a). Astragaloside IV inhibits renal tubulointerstitial fibrosis by
blocking TGF-beta/Smad signaling pathway in vivo and in vitro. Exp. Biol. Med.
(Maywood) 239, 1310–1324. doi: 10.1177/1535370214532597
Wang, L., Chi, Y. F., Yuan, Z. T., Zhou, W. C., Yin, P. H., Zhang, X. M.,
et al. (2014b). Astragaloside IV inhibits the up-regulation of Wnt/beta-catenin
signaling in rats with unilateral ureteral obstruction. Cell Physiol. Biochem. 33,
1316–1328. doi: 10.1159/000358699
Wang, L., Wang, L., Song, R., Shen, Y., Sun, Y., Gu, Y., et al. (2011). Targeting
sarcoplasmic/endoplasmic reticulum Ca(2)+-ATPase 2 by curcumin induces
ER stress-associated apoptosis for treating human liposarcoma. Mol. Cancer
Ther. 10, 461–471. doi: 10.1158/1535-7163.MCT-10-0812
Wang, X., Wang, Y., Hu, J. P., Yu, S., Li, B. K., Cui, Y., et al. (2016). Astragaloside IV,
a natural PPARgamma agonist, reduces abeta production in Alzheimer’s Disease
through inhibition of BACE1. Mol Neurobiol doi: 10.1007/s12035-016-9874-6
[Epub ahead of print].
Wang, Z. S., Xiong, F., Xie, X. H., Chen, D., Pan, J. H., and Cheng, L. (2015).
Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic
nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrol.
16:44. doi: 10.1186/s12882-015-0031-7
Wold, L. E., Dutta, K., Mason, M. M., Ren, J., Cala, S. E., Schwanke, M. L., et al.
(2005). Impaired SERCA function contributes to cardiomyocyte dysfunction
in insulin resistant rats. J. Mol. Cell Cardiol. 39, 297–307. doi: 10.1016/j.yjmcc.
2005.03.014
Xu, X. L., Chen, X. J., Ji, H., Li, P., Bian, Y. Y., Yang, D., et al. (2008).
Astragaloside IV improved intracellular calcium handling in hypoxia-
reoxygenated cardiomyocytes via the sarcoplasmic reticulum Ca-ATPase.
Pharmacology 81, 325–332. doi: 10.1159/000121335
Xu, X. L., Ji, H., Gu, S. Y., Shao, Q., Huang, Q. J., and Cheng, Y. P. (2007).
Modification of alterations in cardiac function and sarcoplasmic reticulum by
astragaloside IV in myocardial injury in vivo. Eur. J. Pharmacol 568, 203–212.
doi: 10.1016/j.ejphar.2007.04.007
Zarain-Herzberg, A., and Alvarez-Fernandez, G. (2002). Sarco(endo)plasmic
reticulum Ca2+-ATPase-2 gene: structure and transcriptional regulation of the
human gene. ScientificWorldJournal 2, 1469–1483. doi: 10.1100/tsw.2002.228
Zarain-Herzberg, A., Garcia-Rivas, G., and Estrada-Aviles, R. (2014). Regulation of
SERCA pumps expression in diabetes. Cell Calcium 56, 302–310. doi: 10.1016/
j.ceca.2014.09.005
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Guo, Cao, Chu, Wang, Zang, Mao, Wang, Wang, Liu, Zhang
and Peng. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 18 December 2016 | Volume 7 | Article 500
